OR WAIT null SECS
Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.
After headlining the American Heart Association 2020 Scientific Sessions, sotagliflozin is once again making waves at the AHA’s annual meeting.
Presented at AHA 2021, the latest data from the SOLOIST and SCORED trials details the effects of sotagliflozin versus placebo therapy on risk of cardiovascular events among patients with diabetes across the spectrum of kidney function.
“In this new analysis of pooled clinical data from the SOLOIST and SCORED trials, sotagliflozin consistently reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function,” said Deepak Bhatt, MD, MPH, executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital, in a statement from Lexicon. “Sotagliflozin, with its dual mechanism of SGLT1 and SGLT2 inhibition, also significantly reduced hemoglobin A1c across the full range of kidney function studied, including patients with severe renal impairment or an estimated glomerular filtration rate between 25 and 30 ml/min/1.73m2, with a magnitude of effect that has not been reported in studies of selective SGLT2 inhibitors.”
Landmark trials designed with the same primary end point, which was total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure, SCORED and SOLOIST returned historic results and subsequent analyses have demonstrated the effects of sotagliflozin were consistent across the spectrum of left ventricular ejection fraction. The most recent AHA 2021 analysis of the trials aimed to assess the influence of eGFR at baseline on the effects of sotagliflozin in these patients.
In the analysis, results indicated there was significant reduction in the primary end point across all prespecified eGFR categories, including those with an eGFR below 30. When assessing a composite end point of heart failure hospitalizations, urgent heart failure visits, myocardial infarctions, strokes, kidney endpoints, and all-cause mortality, results suggested sotagliflozin use was associated with significant reductions across all prespecified eGFR categories.
For more on this analysis and how it adds to our understanding of sotagliflozin and SGLT1/2 inhibition, Practical Cardiology reached out to Bhatt and that conversation is the subject of the following AHA 2021 House Call.
This study, “Cardiovascular Benefits of Sodium Glucose Cotransporter-1/2 Inhibition With Sotagliflozin Across Baseline Kidney Function,” was presented at AHA 2021.